$2.15
0.08[3.86%]
Last update: 5:40PM Get Real Time Here
Invivyd
(NASDAQ:IVVD)Latest News for Invivyd Stock (NASDAQ:IVVD)
Invivyd Stock (NASDAQ: IVVD)
Categories: All
Monday, April 15, 2024
Friday, April 12, 2024
Friday, April 05, 2024
- Invivyd shares are trading higher after the company announced PEMGARDA is available for purchase in the U.S. and said it sees initial FY24 PEMGARDA net product revenue guidance in the range of $150 million to $200 million.Benzinga Newsdesk - Apr 5, 2024, 8:19AM
- Guggenheim Upgrades Invivyd to Buy, Announces $9 Price TargetBenzinga Newsdesk - Apr 5, 2024, 8:13AM
- Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market SessionAvi Kapoor - Apr 5, 2024, 8:01AM
Thursday, April 04, 2024
- Invivyd Sees FY24 Initial PEMGARDA Net Product Revenue $150M-$200MBenzinga Newsdesk - Apr 4, 2024, 4:05PM
- Invivyd's PEMGARDA Commercially Available In U.S. For Pre-Exposure Prophylaxis Of COVID-19 In Certain Adults And Adolescents With Moderate-To-Severe Immune CompromiseBenzinga Newsdesk - Apr 4, 2024, 4:03PM
Thursday, March 28, 2024
Tuesday, March 26, 2024
- Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Mar 26, 2024, 1:45PM
- Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Mar 26, 2024, 10:36AM
- Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 26, 2024, 8:00AM
- Invivyd shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $4 to $10.Benzinga Newsdesk - Mar 26, 2024, 7:07AM
- Morgan Stanley Upgrades Invivyd to Overweight, Raises Price Target to $10Benzinga Newsdesk - Mar 26, 2024, 5:28AM
Monday, March 25, 2024
- Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Mar 25, 2024, 2:44PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Mar 25, 2024, 1:30PM
- Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On MondayAvi Kapoor - Mar 25, 2024, 10:32AM
- FDA Gives Emergency Use Nod To Invivyd's Antibody To Prevent COVID-19 Infection In Adults, Adolescents With Weak Immune SystemVandana Singh - Mar 25, 2024, 9:44AM
- HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $15 Price TargetBenzinga Newsdesk - Mar 25, 2024, 8:59AM
- Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 25, 2024, 8:03AM
Friday, March 22, 2024
- Invivyd Shares Resume TradeBenzinga Newsdesk - Mar 22, 2024, 4:00PM
- Invivyd Shares Halted On Circuit Breaker To The Upside, Stock Now Up 42.4%Benzinga Newsdesk - Mar 22, 2024, 3:58PM
- Invivyd shares are trading higher after the company announced that PEMGARDA received emergency use authorization from the FDA for the pre-exposure prophylaxis of COVID-19. The company announced interim exploratory data on VYD222 from its ongoing CANOPY clinical trial.Benzinga Newsdesk - Mar 22, 2024, 3:56PM
- Trading Halt: Halt status updated at 3:45:00 PM ET: Quotation Resumption: News and Resumption TimesBenzinga Newsdesk - Mar 22, 2024, 3:45PM
- Invivyd Says These Interim Clinical Efficacy Data Are Exploratory And Not Part Of The Primary Immunobridging Endpoint Of The CANOPY Clinical Trial, Secondary Endpoint Of Symptomatic COVID-19 Events In CANOPY Is Unrelated To Regulatory Filing Or Review, But May Be Hypothesis Generating For Future Invivyd Discovery And Development WorkBenzinga Newsdesk - Mar 22, 2024, 3:31PM
- Invivyd Announces Interim Exploratory Data On VYD222 From Ongoing CANOPY Clinical TrialBenzinga Newsdesk - Mar 22, 2024, 3:29PM
- Invivyd Says Product Availability In U.S. Anticipated Imminently; Expects Existing Total Cash And Cash Equivalents Will Enable To Fund Operating Expenses And Capital Expenditure Requirements Into Q4 Of 2024Benzinga Newsdesk - Mar 22, 2024, 3:08PM
- Invivyd Announces FDA Authorization For Emergency Use Of PEMGARDA For Pre-Exposure Prophylaxis Of COVID-19Benzinga Newsdesk - Mar 22, 2024, 3:07PM
- Invivyd Shares Halted, News PendingBenzinga Newsdesk - Mar 22, 2024, 1:17PM
- Trading Halt: Halted at 1:10:51 p.m. ET - Trading Halt: Halt News PendingBenzinga Newsdesk - Mar 22, 2024, 1:10PM
Monday, February 12, 2024
Thursday, January 18, 2024
- Invivyd shares are trading lower after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $5 to $15.Benzinga Newsdesk - Jan 18, 2024, 10:17AM
- Apple To Rally Over 23%? Here Are 10 Top Analyst Forecasts For ThursdayAvi Kapoor - Jan 18, 2024, 7:50AM
- HC Wainwright & Co. Maintains Buy on Invivyd, Raises Price Target to $15Benzinga Newsdesk - Jan 18, 2024, 6:16AM
Wednesday, January 03, 2024
Tuesday, December 19, 2023
- Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Dec 19, 2023, 1:34PM
- Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On TuesdayAvi Kapoor - Dec 19, 2023, 10:19AM
- Morgan Stanley Upgrades Invivyd to Equal-Weight, Raises Price Target to $4Benzinga Newsdesk - Dec 19, 2023, 9:10AM
Monday, December 18, 2023
- Nasdaq Gains 100 Points; Biomerica Shares Spike HigherAvi Kapoor - Dec 18, 2023, 2:21PM
- Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Dec 18, 2023, 1:05PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Dec 18, 2023, 12:32PM
- Crude Oil Rises 3%; US Housing Market Index Increases In DecemberAvi Kapoor - Dec 18, 2023, 12:17PM
- Why Is COVID-19 Antibody Focused Invivyd Stock Trading Over 150% Higher Today?Vandana Singh - Dec 18, 2023, 11:55AM
- Invivyd shares are trading higher after the company announced initial results from its CANOPY Phase 3 trial of VYD222.Benzinga Newsdesk - Dec 18, 2023, 11:09AM
- Invivyd Announced Initial Results From The Ongoing CANOPY Phase 3 Trial Of VYD222, A Broadly Neutralizing, Half-life Extended Monoclonal Antibody Candidate, For The Prevention Of Symptomatic Covid-19Benzinga Newsdesk - Dec 18, 2023, 7:54AM